Immunology Research and Perspectives

https://irp.cultechpub.com/irp

Cultech Publishing

Review

Immunogenomic Remodeling in the Postpartum Period: Molecular Mechanisms, Biomarkers, and Precision Maternal Health

Zulaihat Abdulkadir Yakub[1,*], Abdullahi Isah Kuba[2]

[1]Department of Nursing, Federal University of Health Sciences, Azare, Nigeria

[2]University of Teaching hospital Gwagwalada, Abuja, Nigeria

[*]Corresponding author: Zulaihat Abdulkadir Yakub, zulahatabdulkadir001@gmail.com

Abstract

The postpartum phase represents a dynamic stage of immune restructuring, as the maternal immune system transitions from the pregnancy-induced tolerant state to an inflammatory and restorative profile. Advances in immunogenomic technologies, including single-cell and spatial gene expression profiling, epigenomic analysis, multiomic integration, immune receptor repertoire sequencing, and machine learning, now allow high-resolution mapping of these processes at molecular, cellular, and tissue levels. This review synthesizes current evidence on postpartum immune profiling, highlighting the rapid reversal of pregnancy-associated immunosuppression, hormone withdrawal, interactions between the microbiome and the immune system, and the formation of long-term reproductive immune memory. We examine how delivery mode (vaginal versus cesarean), genetic variants, epigenetic modifications, and non-coding RNAs contribute to divergent postpartum outcomes, including susceptibility to infection, autoimmune flares, hypertensive complications, postpartum depression, and delayed wound healing. Integrative immunogenomic studies have identified specific predictive biomarkers, such as sustained inflammatory signaling molecules (interleukin-6, tumor necrosis factor-alpha), cell-type-specific gene expression signatures, and microbiome-derived markers, that outperform conventional clinical variables in forecasting maternal complications. These biomarkers enable precision postpartum medicine by guiding individualized risk assessment, early diagnosis, and targeted interventions. However, significant gaps remain in longitudinal datasets, global cohort representation, standardization of methodologies, and clinical implementation, particularly in low-resource settings. Future directions include population-scale immunogenomic surveillance, artificial intelligence-driven predictive modeling, integration of wearable biosensors, and development of personalized postpartum care frameworks. By harnessing immunogenomic biomarkers, precision medicine can redefine maternal recovery and improve outcomes through tailored prevention and management of postpartum morbidity.

Keywords

Postpartum immunity, Immunogenomics, Maternal health outcomes, Immune adaptation, Multiomics profiling, Precision medicine

Article History

Received: 27 November 2025 Revised: 17 March 2026

Accepted: 21 April 2026 Available Online: 24 April 2026

Graphical Abstract



1. Introduction

During pregnancy, the maternal immune system is subject to radical changes to prevent the formation of responses to the semi-allogeneic fetus, and these changes continue throughout the postpartum period [1]. It is an important dynamic immunological environment with dramatic changes in leukocyte population and gene expression patterns that promote pregnancy and later maternal recovery [2]. As noted in the past, assessment of postpartum immunological health has been limited by methodological flaws, which do not necessarily reflect the complexity of the underlying changes in the immune state of the mother during the recovery period [3]. However, the recent developments in immunogenomics offer an opportunity for enhanced precision postpartum care based on emerging data to break these complexities, which are molecular prisms through which to interpret the genomic immune signatures of postpartum health outcomes [4]. Although such a possibility exists, the exact processes between individual genomic immune footprints and diverse health outcomes after delivery have not been well defined yet, and this is a gap in the existing knowledge that this review will fill.

In particular, this review will discuss how a multiomic (including transcriptomic, epigenomic, proteomic, and cytomic) approach can explain the complex network of immune responses that is maintained after delivery, therefore affecting the well-being of the mother [4]. These integrative studies promise the possibility of new biomarkers and therapeutic targets for postpartum immune-mediated diseases that include autoimmune exacerbations to peripartum infections. Moreover, these intricate immunological changes should be comprehended because of the significant changes in gene expression in maternal macrophages of chorioamniotic membranes in labor and the evidence of certain cellular responses that might last into the postpartum period and determine the recovery [5]. This involves differentiated gene expression and protein concentration in the immune activities, which is witnessed in interpubic tissue remodelling, which is more prevalent in the early postpartum period rather than the latter period of pregnancy [6].

Such molecular knowledge is especially useful in explaining the phenomenon of reproductive immune memory that can play a role in the different susceptibility to pregnancy problems in primigravidae [7]. These immunological changes might be predicted by developing focused transcriptional panels, which will monitor these changes and identify the

occurrence of negative events at an early stage in the postpartum period [3]. Based on the possibility of using minimally invasive whole blood samples and high-frequency sampling procedures, this method would allow mapping in more detail and thoroughly the inter-individual diversity of immune responses in their application in postpartum health [3].

Combined with clinical metadata, multiomic data, and especially proteomics, have the potential to enhance the predictive power of many health outcomes greatly, compared to analysis of a single omic alone [4]. This combined method can shed light on how different molecular signatures, which are based on different areas of biological life, intersect to shape postpartum immune processes, making it easier to identify critical immunological processes that were involved in either a healthy recovery process or led to adverse outcomes [8]. This type of extensive immunogenomic imaging, which is particularly crucial in conjunction with rigorous clinical phenotyping, is pivotal to the uncovering of the obscure mechanisms that lay the foundation of different postpartum health outcomes of the mother [5].

In this review, a closer look will be taken at the potential of different delivery modes, i.e., Caesarean delivery vs. vaginal delivery, to provoke divergent maternal immune responses and genomic signatures, which could contribute to the long-term maternal health outcomes [9]. This comparative study will illuminate the way the physiological stress of labor, immune cell infiltration into the myometrium, and uterine vascular remodeling define the immune environment in the postpartum period [10]. Moreover, it is important to comprehend postpartum immune changes since the possible issues may include postpartum preeclampsia that may develop until the sixth week following a seemingly healthy pregnancy and may be characterized by severe maternal morbidity [11]. This indicates that effective immunogenomic research is needed in order to identify the involved unique molecular basis of these delayed-onset complications and also to distinguish them from regular postpartum recovery patterns.

The complex interaction of these issues makes a complex multiomic procedure in order to fully describe the recalibration of the immune system after pregnancy, furthering conventional methods to incorporate the advanced immunogenomic approaches [12]. This review will thus be a synthesis of the existing literature on the use of immunogenomics for the recovery of the immune system in the mother, which will explain the interplay between genetic effects and environmental factors that control postpartum health. Multiomic studies offer a solid framework for building a complete atlas of immune programming in pregnancy and eventually help predict biologically realistic postpartum outcomes [4].

This will allow the expansion of insight into the immunopathology, which leads to poor pregnancy outcomes and postpartum morbidities, to be able to create new immunodiagnostic means and tailored interventions [13]. This integrative approach is especially important considering the great immunological changes upon pregnancy, such as the change in gene expression of the mother, which is closely intertwined with parturition and preterm birth [4,5]. This interaction between the maternal physiology and the genome highlights the value of omic profiles in forecasting gestational age and the duration to birth in normal and problematic pregnancies [3].

Such advanced technologies as mass cytometry and proteomic methods, as well as transcriptomic and metabolomic systems, provide an incomparable understanding of the complex measures of regulation of the immune system during pregnancy and in the postpartum period [4]. These developments, consequently, will revolutionize our perspective on the intricate temporal immune regulation that controls maternal adaptation and healing [4]. This can also be used to explain the role of acute-phase proteins and their interaction with molecular signatures in determining postpartum health outcomes, as done in the case of explaining post-acute outcomes of viral infections [14].

The idea of integrating proteomic analysis, in particular, allows getting a comprehensive picture of the circulating effectors of immune responses, which is highly informative regarding the systemic immunological alterations that take place in the course of postpartum recovery [4]. This involves the determination of certain protein biomarkers that have been associated with inflammatory processes and tissue remodeling, including vitamin D-binding protein and gelsolin [15]. Moreover, detailed examination of these protein profiles can identify new cascades of immune activation or suppression that can give a more detailed insight into the physiological changes that took place in the maternal system after delivery [16].

2. Methods

This study employed a comprehensive literature-based and integrative immunogenomic framework to examine immune adaptations in the postpartum period and their impact on maternal health outcomes. Following established integrative review principles, articles, high-impact journals, and other relevant data published from 2020-2025 were obtained through databases (PubMed, Scopus, and Web of Science) using keywords such as postpartum immunogenomics, maternal immune adaptation, single-cell RNA sequencing, and immune biomarkers. Relevant, high-quality, and methodologically sound studies were included in the analysis.

Quantitative and qualitative information from genomic, transcriptomic, epigenomic, and proteomic studies was systematically retrieved and integrated using multiomic integration strategies, which allow the combination of heterogeneous molecular datasets to identify consistent signatures across modalities [17]. This approach was complemented with machine learning and computational modeling techniques to detect predictive immunogenomic patterns and guide interpretation [18]. Multiomic integration studies, longitudinal cohort studies, and mechanistic

experimental research were included to provide a comprehensive view of postpartum immune dynamics, focusing on predictive biomarkers, immune memory, and risk factors for complications.

Where available, data on potential confounding variables, including socioeconomic status, nutritional status, comorbidities, medication use, and environmental exposures, were recorded and incorporated into the integrative analyses to reduce bias and improve interpretability. Information on sample size and statistical power of the included studies was also considered. Many studies did not explicitly report power calculations, particularly for rare postpartum outcomes such as sepsis or exacerbation of autoimmune conditions; as a result, the ability to detect significant associations for these rare events may be limited.

The synthesized data were then presented in thematic, tabular, and narrative formats to highlight technological innovations, clinical significance, and gaps in knowledge in postpartum immunogenomic studies.

3. The Postpartum Immune Environment

With this broad overview, the author engages the multistage immune environment in the postpartum period, where the complex of physiological and molecular transformations determines the critical period [17]. The postpartum period is a distinctly dynamic period of immunological change, as the maternal immune system shifts out of the hyper-tolerative, pregnancy-promoting environment and into a more activated and restorative condition. In this section, the process by which immune rebounds occur, how innate and adaptive immunity are regulated, how sudden changes in hormones affect the immune system, and how the microbiome changes and the clinical implications of immune deregulation in the postpartum period will be studied [17,18]. These processes are necessary to understand the maternal susceptibility to infection, autoimmune exacerbation, mental health problems, and systemic inflammatory complications [18,19].

3.1 The Effects of Immune Activation

During pregnancy, there are deep, implicit changes in immunology focused on the protection of the fetus without impairing the immune capacity of the mother. After birth, such adaptations shift fast and lead to a strong turnaround of immune activation [17,20]. The rebound can be described by enhanced inflammatory cytokine generation, reactivation of formerly suppressed immune pathways, and recovery of normal leukocyte transit. Gestation changes maternal immunity through balancing cytokines, redistribution of immune cells, and metabolic factors to guarantee fetal tolerance [20]. The postpartum change to these regulatory states leads to a temporal condition where immune surveillance becomes stronger, and it may make one more vulnerable to inflammatory diseases or infections.

Recent multiomic immune profiling analyses show that there is an abrupt switch in transcriptomic and metabolic changes immediately after delivery, which is a sharp transition to an increased immune responsiveness [18]. These alterations are not only the circulating immune cells but also tissue-specialized populations that are all related to the involution of the uterus and wound healing. Although this immune rebound is not only physiologically required to recover from parturition and protect against pathogenic infections, but also possible to predict sepsis or over-inflammation, especially when the process is accelerated and amplified in response to delivery complications [21].

3.2 Modulation of Innate and Adaptive Immune Responses Following Childbirth

The postpartum period is characterized by extensive modulation in terms of innate and adaptive immune systems. The innate immune system is hyperresponsive, as neutrophil counts, monocyte activation, and acute-phase reactants are increased as a component of the systemic inflammatory response to childbirth trauma [22]. At the same time, the adaptive immune cells, such as T and B lymphocytes, are functionally reprogrammed, which is evidence of the loss of pregnancy-related immunosuppression [17,23].

Neutrophils and macrophages have important roles in the repair of the uterus postpartum, where they help in clearing debris and remodeling. Gene-expression patterns of immune cells indicate that the body shows increased inflammatory signaling pathways, such as IL-1β, TNF-α, and NF-κB activation, that are required to induce tissue repair but are also markers of increased systemic inflammation [24]. The adaptive immunity also recalibrates synchronously, and the $CD4^+$ and $CD8^+$ T-cell subsets alter their pregnancy-altered tolerogenic phenotype towards a more active cytotoxic and helper phenotype [25]. The changes affect the postpartum reactions to the pathogens and vaccines and the viral reactivations of the latent virus.

Notably, adaptive immune tuning following childbirth does not just fade away with time; it is now beginning to be reported that long-term memory T cells, NK cell groups, and regulatory T-cell (Treg) groups endure months and even years after childbirth following epigenomic imprinting [26]. This immunological memory of pregnancy implies that pregnancy induces sustained immune programming, which determines maternal health trajectories.

3.3 Hormonal Immune Shifts After Childbirth

The prominent aspect of the postpartum immune modulation is the drastic decrease of estrogen, progesterone, human chorionic gonadotropin (hCG), and placental corticotropin-releasing hormone (CRH) levels, which are significantly

decreased in hours after childbirth. Such hormonal changes produce cascade effects on the activities of the immune cells and the regulation of the cytokines [21,23].

The conditions of high progesterone and estrogen during pregnancy inhibit pro-inflammatory processes, promote Treg growth, and regulate innate immune tolerogenic mechanisms. These immunosuppressive effects are abruptly withdrawn by their postpartum degradation, with the consequence that a burst of inflammatory signaling, reactivation of immune cells, and accelerated oxidative stress follow [23]. Cortisol, or an elevation in cortisol during late gestation and labor, also falls rapidly after childbirth as well, which increases immune rebound and inflammation tone.

Maternal mood, metabolic regulation, and neuroimmune interactions are also affected by these hormonal changes. A number of studies associate postpartum hormonal decrease with disturbed cytokine-mediated neural signaling, which could cause postpartum depression by way of neuroinflammatory processes [23]. Therefore, the interplay of the endocrine and immune systems is the focus of the complexity of the postpartum immune response.

3.4 Microbiome-Immune Interactions in the Early Postpartum

After childbirth, the maternal microbiome undergoes significant restructuring of the microorganisms, and the alterations cause a powerful impact on the immune activity. The postpartum alterations in gut, vaginal, and breast milk microbiota have an impact on the local and systemic immunity [17]. Microbiome-derived metabolites such as short-chain fatty acids (SCFAs) control immune cell development, Treg activity, and cytokine inflammation.

The disruption of immune homeostasis and the increase in inflammation can be caused by postpartum dysbiosis, which is normally introduced by contact with antibiotics, the delivery mode, stress, and dietary modifications [19]. Postpartum healing is also affected by vaginal and uterine changes in microbial composition, which affects uterine involution and predisposition to endometritis. Human breast milk microbiome changes affect the development of neonatal immunity and, at the same time, regulate the maternal mucosal immunity.

Due to the high interactions between microbial communities and hormonal and metabolic pathways, the microbiome-immune crosstalk is now considered to be a primary element of postpartum immune restoration.

3.5 Clinical Implications of the Immune Dysregulation During the Postpartum Window

Early postpartum immune dysregulation has serious clinical implications. The sudden inflammatory relapse and hormonal withdrawal may increase the susceptibility to infections, autoimmune exacerbations, cardiovascular complications, and mental health disorders [18,21]. It is interesting to note that dysregulated immune responses are also predisposing factors to postpartum sepsis, which is one of the major causes of maternal morbidity and mortality worldwide [21].

The presence of elevated acute-phase inflammatory proteins, including C-reactive protein, serum amyloid A, and fibrinogen, which are affected by innate immune activation, may be a good early biomarker of postpartum infection or inflammatory dysregulation [24]. Preeclampsia-associated complications, which are persistent in the postpartum period, are also likely to have a role in postpartum inflammatory surge since the dysfunction of endothelium and the activation of the immune system can be delayed in women at high risk [22].

The long-term effects of postpartum immune dysregulation could also be excessive exposure to autoimmune diseases, rheumatoid arthritis, and thyroiditis, which have been observed to exacerbate in the months following birth. Moreover, neuroimmune signaling can be affected by the immune-endocrine imbalances of the postpartum period, exposing women to the risk of postpartum depression and anxiety [23].

Postpartum immunity is a period of vulnerability as well as a period of early detection of immune complications. The knowledge of these mechanisms will be critical to enhancing maternal health outcomes by early intervention, precision monitoring, and specific prevention initiatives.

4. Maternal Health Research: Immunogenomic Approaches

4.1 Whole-Genome and Whole-Exome Sequencing

The current developments in immunogenomics have transformed how we study maternal immune regulation and postpartum immunodynamics and have offered the ultimate solution in the profiling of immune responses. Leading the pack in such methods, whole-genome and whole-exome sequencing allow the comprehensive characterization of genetic variants that govern the maternal immune responses during and after pregnancy [27]. These high-throughput methods reveal inherited and de novo determinants of genetic factors that could predispose mothers to immune dysregulation or unfavorable pregnancy outcomes by the identification of single-nucleotide polymorphisms, copy number variations, and rare mutations [28]. These sequencing initiatives also offer a baseline to which the interactions of genetic architecture with environmental and hormonal variants to regulate immune recovery after delivery could be mapped. Table 1 above summarizes the key immunogenomic technologies currently applied to postpartum

immunological research, highlighting their resolution, primary data output, and specific relevance to the unique immune reprogramming that occurs after pregnancy.

Table 1. Immunogenomic technologies and their applications in postpartum research.

Technology	Resolution	Primary Data Type	Major Postpartum Applications	References
Bulk RNA-seq	Population	Transcriptome	Identification of inflammatory rebound signatures	[4,29]
Single-cell RNA-seq (scRNA-seq)	Single cell	Transcriptome + cell state	Rare immune subsets, trajectory analysis, tissue-specific responses	[5]
Spatial transcriptomics	Spatial + single cell	Transcriptome + location	Uterine involution, mammary gland immune zoning	[10]
DNA methylation/ATAC-seq	Epigenomic	Chromatin accessibility	Persistent immune memory, hormonal imprinting	[1,26]
T-cell receptor (TCR)/B-cell receptor (BCR) repertoire sequencing	Clonality	Adaptive receptor diversity	Postpartum immune memory, autoimmunity risk	[27]
Mass cytometry (CyTOF)	Protein (30-50 markers)	Surface + intracellular	Immune cell phenotyping during rebound	[4,29]
Multiomic integration + ML	Systems level	Genomics + proteomics + metabolomics	Predictive modeling, immune clock, biomarker panels	[4,29]

Bulk RNA-seq remains widely used for detecting broad inflammatory rebound signatures in peripheral blood, while single-cell and spatial transcriptomics provide higher-resolution insights into rare immune subsets, dynamic cell-state trajectories, and tissue-specific phenomena such as uterine involution and immune zoning in the mammary gland. Epigenomic approaches (DNA methylation and ATAC-seq) reveal persistent chromatin changes linked to hormonal imprinting and long-term immune memory, and TCR/BCR sequencing tracks clonal adaptive responses associated with postpartum autoimmunity risk. Protein-level phenotyping is achieved through CyTOF, and the integration of multiomic datasets with machine learning is increasingly employed to build predictive models, construct postpartum "immune clocks," and identify clinically actionable biomarker panels. Together, these technologies enable a comprehensive, multi-scale understanding of the dramatic immune shifts that characterize the postpartum period.

4.2 Single-Cell RNA Sequencing

ScRNA-seq has helped us to further examine the complexity of maternal immune cells in a previously unexplored depth [27,29]. Through ScRNA-seq, it is possible to identify unique subsets of immune cells, their activation state, and transcriptional profiles in various tissues, such as peripheral blood, decidua, and the maternal-fetal interface, which is important in understanding how these cells mediate postpartum complications caused by inflammation [30]. The resolution of heterogeneity on a single-cell scale will allow researchers to identify subtle changes in immune performance that could occur before a clinical symptom of an illness, including preeclampsia or postpartum infection [27,28].

4.3 Epigenomic Profiling

Another source of information regarding maternal immune regulation is epigenomic tools, such as DNA methylation profiling and histone modification mapping [27,31]. Pregnancy triggers certain epigenetic modifications to regulate the expression of immune genes to accommodate the semi-allogeneic fetus, and these modifications may continue even in the postpartum period [27]. To illustrate, alterations in methylation of key immune regulatory genes can impact the production of cytokines and T-cell differentiation and activation of innate immunity, thus determining the postpartum immune environment [30]. These are further regulated by histone modifications, such as acetylation and methylation, which control the chromatin accessibility and transcriptional programs that regulate immune cell identity and function, providing potential biomarkers of maternal immune status and resilience [31].

4.4 Transcriptomic Analyses

These methods are complemented by transcriptomic analyses, which profile the expression patterns of thousands of genes at once and offer a dynamic overview of the position of immune activation and resolution postpartum [28,32]. Combined with transcriptomic analyses of peripheral blood mononuclear cells, placental tissues, or uterine samples, the researchers can determine the signatures of inflammation, repair, and tissue remodeling, which are specific to the postpartum period [28]. These signatures can be used to identify dysregulated processes, such as hyperinflammatory reactions or failed regulatory processes that can lead to complications, such as delayed postpartum recovery, infections, or autoimmune exacerbations [29].

4.5 Multiomic Integration

Multiomic data integration, comprising genomics, transcriptomics, proteomics, and metabolomics, provides an overview of maternal immune functioning [27,33]. Through the layer-based approach, investigators have the ability to assemble networks that are interacting with each other to capture the convergence of genetic variants, epigenetic

changes, and protein signaling to control the immune responses. Multiomic integration can be used to discover molecular hubs and pathways that promote immune resilience or vulnerability in order to deploy interventions that can be tailored to maximize maternal health [28,33]. As an example, transcriptomic and proteomic data can be combined to determine a post-transcriptional control of cytokines or chemokines that have a central role in postpartum tissue repair [30].

4.6 Computational Immunogenomics

These large-scale datasets can only be harnessed through computational immunogenomics and machine learning methods [27,34]. It has been demonstrated that machine learning models can discover predictive biomarkers of adverse maternal outcomes, discovering nonlinear and complex associations between genes, proteins, metabolites, and clinical phenotypes [34]. Such algorithms are better than traditional statistical methods at handling large-scale (high-dimensional) data, bias reduction, controlling confounding, and missing data [34]. Using pattern recognition and predictive modeling, computational models are able to predict immune patterns, allowing early intervention in mothers who are going to develop complications like postpartum bleeding, infections, or autoimmune exacerbations [33].

Moreover, a convergence of multiomic data with machine learning makes it possible to build an immune clock that traces chronological regulation of immune characteristics during the pregnancy span and into the postpartum period [28]. These models can detect the abnormalities of the expected patterns, which is an indication of weakness or maladaptation. The example of such an increase is the delay in the normalization of inflammatory mediators or the inappropriate activation of innate immune pathways, which can be a sign of increased vulnerability to sepsis or the inability to repair tissue [28,29]. This predictive potential is especially useful in the case of personalized medicine approaches, where specific biological preventive or therapeutic therapies might be precisely designed depending on individual immunogenomic signatures [27,34].

4.7 Translational Applications

These immunogenomic studies are applied in areas outside basic research to translational maternal healthcare [27]. High-resolution immune profiling could ameliorate the maternal vaccination strategies by determining the most appropriate time and target antigens that induce protective immunity devoid of causing adverse inflammatory responses [27,35]. Moreover, the combination of omics data, electronic health records, and population-level data can help accurately identify the risk, thereby allowing clinicians to prevent and predict the occurrence of postpartum complications more accurately [34]. These strategies can be used to maximize the maternal and neonatal outcomes, especially in high-risk groups or environments with scarce resources [35].

Although progress has been made, there are still obstacles to percolating all the potential of immunogenomics in maternal health. There is a need to standardize data acquisition, sample processing, and analytical pipelines to achieve reproducibility and comparability among studies [28]. Moreover, ethical concerns such as the privacy of genomic data, fairness in the access to testing, and informed consent are essential in the responsible application of such technologies in clinical practice [27]. The solutions to these problems involve an interdisciplinary approach involving genomics, immunology, computational biology, and clinical fields.

Immunogenomic technologies are revolutionizing maternal health studies by making it possible to map the dynamics of immunogenomic processes during the entire peripartum phase with accuracy and high resolution. Whole-genome and exome sequencing and scRNA-seq, epigenomic profiling, and multiomic integration techniques, with sophisticated computational and machine learning analysis, enable the previously unimaginable understanding of the processes behind maternal immune adaptation, postpartum recovery, and susceptibility to adverse outcomes. Combining these technologies is likely to support the creation of predictive biomarkers, patient-specific treatments, and targeted therapies, which are then expected to enhance the health of both the mother and the baby [27,35].

5. New Directions in Immunogenomics Applicable to Postpartum Adaptation

The postpartum period is one of the most urgent periods of immune recalibration of the mother, in which the pregnancy-induced immunological adaptations are eliminated, and homeostasis is restored. Recent innovations in immunogenomics have shed light on the molecular basis underlying this transition and have given unparalleled insights into the mechanism of systemic and localized immune remodeling.

5.1 Detection of Postpartum-Specific Immune Gene Modules

New data suggest that unique gene sets are either activated or suppressed during the postpartum phase, and this phenomenon points to orchestrated immune recalibration [36,37]. These modules embrace innate and adaptive immunity, and this is emphasized by using the main regulatory nodes that can be used to forecast recovery or postpartum complications. Combining the transcriptomic, epigenomic, and proteomic data, the researchers will be able to chart the time dynamics of such gene networks, disclosing the long-term immunological changes that do not merely endure the immediate postpartum period [38]. These analyses can serve as a blueprint for precise medicine methods, which may offer possible biomarkers of postpartum depression or autoimmune flare-ups [39].

5.2 Non-Coding RNA (miRNAs, lncRNAs) Role in Maternal Immune Regulation

Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have emerged as important regulators of the postpartum immune response. These molecules modulate gene expression after delivery, thereby influencing cytokine release, lymphocyte activation, and the resolution of inflammation [40,41]. Dysregulation of specific ncRNAs may predispose women to excessive inflammatory responses or impaired tissue repair, making them potential therapeutic targets. Furthermore, multi-omic analyses integrating RNA profiling with proteomic and metabolomic data provide a more accurate representation of the regulatory networks mediated by these non-coding transcripts, which are only beginning to be elucidated [42,43].

5.3 TCR/BCR Repertoire Sequencing for Postpartum Immune Memory

The TCR and BCR repertoire high-throughput sequencing provides a granular perspective of the adaptive immune memory after childbirth [44]. These methods allow for the process of identification of clonal expansions and repertoire changes that are indicative of residual pregnancy-linked immune adaptations and responses to environmental exposures, such as vaccination. The profiling of these repertoires offers information regarding vulnerability to postpartum infections, autoimmune events, and the effectiveness of maternal immunization mechanisms [45,46].

5.4 Biomarkers of Immunogenomics, Which Anticipate Postpartum Complications

Combination immunogenomic studies have helped in the identification of candidate biomarkers that are predictive of postpartum complications. The application of transcriptomic signatures with machine learning algorithms has revealed important genes and pathways that cause excessive inflammation, impaired uterine involution, or changes in neuroimmune signaling [47-49]. Such biomarkers have the potential to consolidate the early risk stratification, which allows the targeted intervention to maximize the maternal recovery and prevent bad outcomes.

5.5 Polygenic Risk Score of Maternal Autoimmune Disease Flares

Genome-wide association data have been used to develop polygenic risk scoring as a tool to predict postpartum exacerbations of autoimmune diseases. The female patient whose polygenic risk score for many disorders, such as systemic lupus erythematosus or rheumatoid arthritis, is high could have increased immunity sensitivity in the postpartum period [47,50]. These scores can be used to inform personalized monitoring and prophylactic interventions coupled with longitudinal immunogenomic profiling to balance the gap between genomic susceptibility and clinical intervention.

5.6 New Findings of Spatial Transcriptomics in Reproductive Tissues

Spatial transcriptomics provides the best resolution of the expression of the genes in an anatomical setting to map the localization and activity of immune cells in reproductive tissues [51,52]. This model has shown that there are dynamic interactions between immune, stromal, and epithelial compartments in the process of postpartum involution of the uterus and lactation. Through imaging spatial changes in cytokine signaling and cellular activation, spatial transcriptomics can give a mechanistic understanding of tissue-specific immune responses, as well as localized targets that can be used to intervene.

All these new immunogenomic trends highlight the potentially revolutionizing nature of multiomic, high-resolution technologies to unravel the mysteries of postpartum immune adaptations. Due to the combination of systemic and tissue-specific data, scientists are able to discover predictive biomarkers, determine regulatory pathways, and finally implement precision interventions to maximize maternal health outcomes [53,54].

6. Immunogenomic Understandings of Important Postpartum Maternal Health Results

A key vulnerability of the postpartum period is that it is a period of extremely fast maternal immune recalibration after the complex changes of pregnancy. Immunogenomic studies have presented significant information on the molecular and cellular pathways that direct maternal recovery with a complex interplay of genetic, epigenetic, transcriptomic, and proteomic interactions. The insights are critical in knowing the susceptibility to postpartum complications and how to optimize maternal care and enhance long-term health outcomes of both mother and child.

6.1 Postpartum Infection Risk and Immune-Genetic Susceptibility

Postpartum infections such as endometritis, urinary tract infections, and wound infections are also major causes of maternal morbidity. Immune-genetic susceptibility is a key factor that predetermines individual risk because the difference in immune-regulatory genes affects the perception of pathogens, cytokine responses, and innate and adaptive immune responses. Multiomic analysis has also revealed the presence of distinct transcriptomic and epigenetic signatures that could lead to delayed immune reconstitution, neutrophil dysfunction, and lymphocyte activation alterations, which could predispose women to infection during the puerperium [42]. The combination of high-throughput proteomic and metabolomic results serves to further demystify the fact that the interaction between

postpartum immune modulation and systemic metabolic status occurs at the systems level, with the value of a system-level methodology in predicting the risk of infection. These results indicate that immunogenomic profiling would eventually inform personalized monitoring approaches and specific interventions to lessen postpartum infectious morbidity [48].

6.2 Hypertensive Disorders and Immunogenomic Imprints Remaining After Delivery

Hypertensive pregnancies, like preeclampsia, have long-term cardiovascular and immune system effects on the mother. Immunogenomic studies show that postpartum women who had a history of preeclampsia have remnants of inflammatory signatures (high expression of pro-inflammatory cytokines, increased expression of endothelial dysregulation genes, and imbalances in immune cell populations) [51]. These molecular prints can be associated with cumulative hypertension, endothelial dysfunction, and higher cardiovascular risks in adulthood. Early detection and personalized postpartum care have a chance with advanced transcriptomic and epigenetic profiling that would help to identify these remnants of immune signatures. Through the awareness of the underlying molecular basis of prolonged immune activation, clinicians can come up with specific interventions that can be used to reduce the long-term cardiovascular complications among affected women.

6.3 Autoimmune Disease Reactivation or Remission During the Postpartum Period

Pregnancy is also linked with significant immunomodulatory actions that are capable of temporarily either enhancing or worsening autoimmune illnesses. In the postpartum period, the reversal of the pregnancy-induced immune tolerance is usually acute, which leads to the reactivation of the disease. Immunogenomic analysis indicates that T-cell and B-cell repertoire alterations are accompanied by epigenetic modification and cytokine imbalance, which cause postpartum autoimmune flare or remission. The combination of transcriptomic, proteomic, and metabolomic data provided by multiomics can be used to identify single risk profiles of autoimmune disease activity. These findings will be vital in shaping the postpartum management approaches, such as immunomodulatory interventions and individualized follow-ups, which may ensure severe exacerbations are avoided and maternal quality of life is enhanced.

6.4 Crosstalk Between Immunity and Genomics in Postpartum Depression

New evidence also relates postpartum depression to neuroimmune dysregulation, and immunogenomic crosstalk is at the center of the pathogenesis. The neuroinflammatory mechanisms, such as microglial activation and cytokine-mediated signaling in the central nervous system, can be altered by changes in gene expression in immune cells and epigenetic changes. Such alterations can balance the activity of the hypothalamic-pituitary-adrenal (HPA) axis, which leads to depressive symptoms. Multiomic profiling makes it possible to estimate the changes in the immune system and neural signaling simultaneously, indicating the presence of certain molecular signatures linked to the severity of postpartum depression. These neuroimmune interactions can be used to develop biomarker-based interventions and new forms of treatment that amplify the immune role in mood disorders in the postpartum period.

6.5 Immunogenomic Adaptations of Lactation

Lactation triggers significant immunogenomic changes, which are indicative of the dual need of maternal and neonatal immune defense. People use transcriptomic studies of mammary tissue and circulating immune cells to demonstrate the dynamic regulation of the genes related to the production of immunoglobulins, cytokine interaction, and leukocyte traffic. These adaptations aid in transferring protective antibodies through breast milk and regulate systemic inflammation in order to aid tissue repair and maternal homeostasis. Combined metabolomic and proteomic studies have found the synchronized processes of nutrient and immune regulation, whose interactions between metabolism and immunity occur during lactation. These insights may be used in interventions to maximize lactational support and promote the development of neonatal immunity.

6.6 Wound Healing and Tissue Regeneration: Postpartum Recovery: Genomic Control

Immunogenomic networks are tightly controlled to coordinate the process of postpartum tissue repair, such as involution of the uterine tissue and healing of the perineum. Temporally regulated genes that regulate extracellular matrix remodeling, angiogenesis, cytokine signaling, and leukocyte recruitment cross-link effectively to induce efficient healing and inhibit atherogenesis, such as hemorrhage or fibrosis [47]. Multiomic techniques with high content can give a map of both cellular and molecular dynamics of postpartum recovery, allowing the identification of key regulatory centers. Knowledge of these paths can be used to create specific therapeutics to hasten the healing process of tissues and enhance patient outcomes after cesarean or perineal trauma.

It can be concluded that immunogenomic technologies could be applied to postpartum maternal health, which offers a holistic model of the intricate interplay of genes, immune cells, and molecular networks at this phase. Through the combination of multiomics with computational analyses, scientists can discover predictive biomarkers and mechanistic information and design interventions to target improved maternal recovery and aid against postpartum complications. These innovations promise to deliver accuracy in maternal care, enhancing immediate and future results for mothers and their babies [43].

The Table 2 below outlines major postpartum complications, their typical onset windows, underlying immunogenomic mechanisms, and emerging biomarkers identified through recent studies. In the early postpartum period (0-6 weeks), infections and sepsis are linked to defective neutrophil function and prolonged innate inflammation. In contrast, postpartum preeclampsia reflects sustained endothelial activation and complement dysregulation with disturbed angiogenic profiles. From the first weeks to 12 months, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and thyroiditis frequently flare due to loss of pregnancy-induced regulatory T-cell suppression and epigenetic demethylation, often accompanied by clonal TCR and BCR expansion and interferon signatures. Postpartum depression is associated with persistent peripheral and central neuroimmune activation involving IL-6, TNF-α, and microglial gene modules alongside HPA-axis dysregulation. Finally, delayed uterine involution and secondary hemorrhage arise from impaired macrophage M1-to-M2 polarization and defective extracellular matrix remodeling, detectable through altered expression ratios of matrix metalloproteinases (MMP-9) and their inhibitors (TIMP-1). Collectively, these immunogenomic signatures offer promising diagnostic and prognostic biomarkers for early detection and targeted intervention in high-risk postpartum women.

Table 2. Postpartum complications and associated immunogenomic signatures.

Complication	Timing	Immunogenomic Features	Potential Biomarkers	References
Postpartum infection/sepsis	0-6 weeks	Impaired neutrophil function, delayed innate resolution	↑ IL-1β, TNF-α, CRP; altered acute-phase proteins	[21]
Postpartum preeclampsia	Up to 6 weeks	Persistent endothelial activation, complement dysregulation	Angiogenic imbalance, inflammatory gene modules	[11]
Autoimmune flare (RA, SLE, thyroiditis)	1-12 months	Loss of Treg suppression, epigenetic demethylation	Polygenic risk scores, TCR clonal expansion	[1, 26]
Postpartum depression	0-12 months	Neuroimmune activation, HPA-axis dysregulation	↑ IL-6, TNF-α in periphery; microglial gene signatures	[23]
Delayed uterine involution/hemorrhage	0-6 weeks	Dysregulated macrophage polarization, extracellular matrix (ECM) remodeling defects	Altered M1/M2 gene modules, collagenase expression	[6]

Several studies have reported differing timelines for postpartum immune recalibration. While some longitudinal analyses suggest that immune homeostasis is largely restored within 6-8 weeks postpartum [1,2], other studies using multiomic profiling and high-dimensional immune phenotyping indicate that complete recalibration may extend to 6-12 months [3,44]. These discrepancies likely reflect differences in study populations, sampling schedules, and immune readouts employed. For instance, cross-sectional studies may underestimate the duration of immune recovery, while longitudinal single-cell or multiomic approaches can capture more subtle, persistent changes. Delivery mode, hormonal status, and ethnic diversity may also contribute to variability. Acknowledging these inconsistencies is critical for interpreting predictive biomarkers and their potential clinical applications. Future studies should standardize sampling and use longitudinal designs across diverse populations to resolve these contradictions.

7. Translational and Clinical Implications

Immunogenomics, as an up-and-coming discipline, promises revolutionary changes in the healthcare of postpartum mothers by connecting the understanding of the molecules with actual clinical implementation. Immunogenomic studies can form the basis of precision medicine approaches to enhance maternal outcomes by revealing the complicated interactions between genes, immune pathways, and environmental factors during and after pregnancy.

7.1 Diagnostic Tools Diagnostic Tools are Developed Using Immunogenomic Signatures

The discovery of the postpartum immunogenomic signature can be used to develop sensitive diagnostic tools that are sensitive enough to detect subtle changes in maternal immune status. A combination of transcriptomic, proteomic, and epigenomic data on a multiomic scale has identified gene modules and molecular signatures that are active or suppressed in the puerperium in a unique way [46]. These are the markers that may be utilized to establish assays to monitor immune recovery, to identify early infection, or to forecast the occurrence of autoimmune flares after childbirth. TCR and BCR profiling of the high-throughput can give a comprehensive perspective on the adaptive immune memory by giving biomarkers of susceptibility to infections and immune dysregulation [48]. Clinical diagnostic translation of these results will not rely on the broad inflammatory markers but rather on specific molecular markers, which allows early intervention and tailored treatment.

7.2 Personalized Postpartum Risk Stratification

Personalized postpartum risk assessment can be done through immunogenomic profiling. Combining multiomic data with computational modeling, such as machine learning and network analyses, makes it easier to classify women according to their risks of infections, hypertensive conditions, autoimmune flares, or postpartum depression. Polygenic risk scoring is a combination of transcriptomic and epigenomic patterns with polygenic risk, which can help to inform about an increased risk of complications and rely on customized monitoring and preventive measures. These techniques record both the temporary and permanent marks of the immune responses, representing a variation in recovery patterns.

Individual stratification based on immunogenomics enables clinicians to distribute resources in an effective manner and offer precision maternal care.

7.3 Possibility to Early Identify Maternal Complications

One of the main translational uses of immunogenomics is in identifying postpartum complications at an early stage. Perturbations of immune gene expression, cytokine concentrations, and epigenetic changes can be detected before clinical signs of preeclampsia, infection, or exacerbations of an autoimmune disease. Combining transcriptomic and metabolomic indicators will be used to measure crosstalk between immune, metabolic, and neuroendocrine pathways, which enhances predictive accuracy. As an illustration, the integration of immune gene signatures and metabolomic data can identify women who might experience delayed wound healing or lactation-associated immune adaptation impairment. Immunogenomic profiling can also enhance the maternal outcomes and decrease the spending on healthcare costs, as it provides an early diagnosis with a possibility of timely interventions. As illustrated in Figure 1, the multiomic integrative framework for precision postpartum care combines transcriptomic, metabolomic, and immune profiling to enhance early detection and improve maternal outcomes.



Figure 1. Multiomic integrative framework for precision postpartum care.

Figure 1 illustrates a comprehensive multiomic architecture for precision postpartum care centered on the integration of diverse biological data layers with clinical metadata. At the core lies clinical metadata, surrounded by high-dimensional molecular inputs from genomics, transcriptomics, epigenomics, proteomics, metabolomics, and microbiome profiling derived from research platforms and bedside monitoring. These data streams converge within a machine-learning layer that generates three primary outputs: individualized risk scores for postpartum complications, validated biomarker panels tailored to specific postpartum time points and predicted clinical trajectories. The outputs inform adaptive clinical trials, evidence-based guideline refinement, and targeted interventions, thereby establishing a continuous learning system for precision maternal care.

This schematic depicts the translational pipeline of current postpartum immunogenomics: a number of high-dimensional data layers, including genomics, epigenomics, transcriptomics (bulk and single-cell), proteomics, metabolomics, and microbiome profiling, are gathered and input into a central machine-learning engine. The integrated model outputs customized products such as continuous personalized risk scores of major complications (infection, postpartum preeclampsia, autoimmune flare, depression); customized biomarker panels optimized by each postpartum time period; predicted immune and clinical dynamics in comparison with healthy reference atlases; and recommendations to action such as increased surveillance and preventive vaccination or individualized anti-inflammatory or antidepressant therapy, and closes the loop between basic discovery and clinical trials and guidelines and real-time bedside and electronic health record practice of truly personal

7.4 Moving Immunogenomics Into Maternal Healthcare Systems

The adoption of immunogenomics into regular maternal practices necessitates workflow and bioinformatics pipeline standardization as well as training clinicians. Immunogenomic data can be added to electronic health records to create a full picture of the maternal immune status as a means of real-time monitoring and decision support [46]. The mass studies are capable of identifying normative postpartum immune trajectories to aid in identifying the difference between physiological and pathological deviations [47]. Integrating these tools into clinical practice aids in predictive and preventive frameworks of care where interventions are based on personalized molecular profiles instead of using the symptoms alone.

7.5 Maternal Genomic Research: Ethical, Legal, and Data Privacy

Immunogenomics applications are associated with serious ethical and legal as well as data privacy concerns. Multiomic and genomic data can be used to convey information concerning the mother, child, and extended family. Researchers require frameworks that can facilitate informed consent, the secure storage of data, and limited access to information to avoid misuse or discrimination. There are communication strategies and counseling that would prevent excessive anxiety or stigmatization using predictive biomarkers. Ethical standards should also provide equal access to immunogenomic developments among varied populations and avoid differences in treatment. The safety of the integration of genomic data into clinical practice heavily depends on legal safeguards and regulations.

Immunogenomics has the potential to transform postpartum maternal healthcare by enabling molecularly informed, patient-centered approaches. Improved maternal outcomes and precision medicine can be achieved through the development of molecular diagnostic tools, personalized risk stratification, and early detection of complications. Implementation would involve systematic collection of patient molecular and clinical data, integration with electronic health records, and application of validated computational risk models to guide clinical decision-making. Effective deployment requires trained personnel, laboratory and bioinformatics infrastructure, secure data management systems, and clear clinical protocols to ensure actionable interpretation of immunogenomic signatures. Additionally, integration into existing healthcare workflows and coordination with multidisciplinary care teams are essential to translate these insights into practical interventions while maintaining ethical standards and robust data governance to ensure equitable and patient-centered care [46,55]. Table 3 below outlines the current challenges and proposed solutions in postpartum immunogenomics, highlighting key areas that need to be addressed for effective implementation.

Table 3. Current challenges and proposed solutions in postpartum immunogenomics.

Challenge	Description	Proposed Solutions	References
Limited longitudinal datasets	Most postpartum immunogenomic studies capture only 1-2 time points, limiting understanding of dynamic immune recovery trajectories.	Establish international longitudinal consortia with harmonized serial sampling protocols; develop postpartum immune reference atlases integrating bulk and single-cell data.	[46,47]
Under-representation of diverse populations	The majority of datasets are derived from high-income countries and predominantly European ancestry cohorts.	Include Low- and middle-income countries. (LMIC) populations; prioritize ancestry-diverse genomic repositories; implement equity-focused recruitment frameworks.	[46,55]
Multiomic data integration complexity	High-dimensional datasets with batch effects, missing modalities, and cross-platform variability hinder reproducibility.	Develop standardized bioinformatics pipelines; open-source AI integration frameworks; interoperable multiomic reference databases.	[46-48]
Clinical translation barriers	Limited availability of validated, cost-effective assays suitable for bedside use; slow integration into electronic health records	Develop whole-blood point-of-care transcriptional panels; integrate immunogenomic dashboards into EHR systems; validate biomarker panels in multicenter trials.	[46,55]
Ethical and privacy concerns	Multiomic maternal data reveal sensitive reproductive and familial genomic information, raising consent and discrimination concerns.	Implement federated learning models; dynamic consent frameworks; encrypted genomic repositories; and regulatory oversight for AI-based maternal risk scoring.	[55]

8. Challenges and Areas of Knowledge Sufficiency

Although immunogenomics can be transformative as far as postpartum maternal health is concerned, there are a number of key challenges and knowledge gaps that pose a limitation to the application of research to clinical practice.

8.1 A Limited Longitudinal Postpartum Immunogenomic Dataset

A significant weakness is the lack of longitudinal immunogenomic studies that can be used to observe dynamic alterations in the maternal immune system during late pregnancy and into the infant's postpartum stage [46]. The majority of the studies are cross-sectional or more concentrated on gestation, and the temporal dynamics of immune recalibration are unknown. In the absence of detailed longitudinal data that is detailed, there is a limit to demarcating

the baseline immune variation with pathological deviation, preventing the development of predictive models of postpartum complications. Multiomic profiling of longitudinal cohorts would be important in giving insights into immune recovery, tissue repair, and also the susceptibility to infections or autoimmune flares.

8.2 Heterogeneity in Genetic Population of the World and Maternal Outcomes

The other challenge to immunogenomic research is population genetic diversity. The responses of immune systems and the predisposition to diseases differ depending on ethnicity, geographic areas, and environments [1,2]. Accordingly, results obtained with homogeneous populations may not be applicable in differentiating other maternal populations, especially in low- and middle-income nations where maternal postpartum morbidity is still elevated. The behaviors of genetic variation, epigenetic regulation, and local environmental exposures to shape maternal immune directions should be understood to develop globally relevant interventions and customized care frameworks.

8.3 Clinical Integration Barriers in Low-Resource Clinical Settings

Ethical issues in the implementation of immunogenomic tools in clinical practice are logistical and infrastructural barriers, particularly in low-resource environments [46]. Multiomic data analysis, high-throughput sequencing, and computational modeling demand high technical expertise, bioinformatics infrastructure, and financial investment. Such resources are limited and could enhance the health inequities that already exist by leaving vulnerable populations with no advantage of precision postpartum care. The solution to these barriers is the implementation of scalable methods with low costs and capacity-building programs to train clinicians and laboratory personnel.

8.4 Problems with Multiomic Data Interpretation

The combination of transcriptomic, proteomic, metabolomic, and epigenomic data imposes computational and analytical difficulties [46]. Multiomic data are very dimensional and usually have intricate interdependencies, which are hard to interpret without advanced machine learning algorithms as well as strong statistical techniques [2]. Moreover, inconsistency in the protocols and preprocessing of data used in the experiments may create bias, which may lower the level of reproducibility across studies. Pipelines should be standardized and analytical frameworks open so that consistent, interpretable results can be formed, which can aid in clinical decision-making.

8.5 Requirement of Standardized Postpartum Immunogenomic Protocols

At the moment, standardized procedures of sampling, processing, and analysis of postpartum immunogenomic data do not exist. The timing of sample collection, type of tissue, and assay methodology differences between studies prevent cross-study comparisons and meta-analyses. The design of postpartum immunogenomic studies, multiomic integration, and reporting standards needs consensus guidelines that would help create a consistent body of evidence that can be confidently applied to clinical practice. The standardization would also ease the process of finding potent biomarkers used to detect infection, autoimmune risk, and other complications affecting mothers, to speed up the process of translation.

9. Assessment of Methodological Quality, Risk of Bias, and Generalizability

While the reviewed studies provide valuable insights into postpartum immunogenomics, it is important to critically evaluate their methodological rigor and applicability. Most studies employed high-throughput techniques such as single-cell transcriptomics, TCR/BCR repertoire sequencing, and multiomic integration; however, sample sizes were often limited, and cohort diversity was restricted, which may introduce selection bias and limit the representativeness of findings. Several studies were conducted primarily in high-income countries and among populations of European ancestry, reducing generalizability to low- and middle-income settings or ethnically diverse populations. Additionally, variations in study design, experimental protocols, and timing of postpartum sampling contribute to heterogeneity and potential measurement bias. While integrative analyses highlight promising predictive biomarkers, these findings should be interpreted cautiously until validated in larger, longitudinal, and ethnically diverse cohorts. Future research should incorporate standardized multiomic pipelines, longitudinal sampling, and transparent reporting to enhance methodological quality, minimize bias, and improve the external validity of immunogenomic insights across global populations.

10. Future Directions

Based on the existing progress and filling the existing gaps, there are a number of potential directions in which the future of postpartum immunogenomic research and clinical implications can be pursued.

10.1 Population-Wide Postpartum Surveillance of Immunogenomic Surveillance

Immunogenomic surveillance on a population level would be able to detect women at risk earlier, before they develop any postpartum complications. Multiomic profiling combined with electronic health records in large-scale cohort

studies would offer normative postpartum immune trajectories as the genetic, environmental, and lifestyle variability are considered [1,46]. This kind of surveillance would assist in preventive intervention, allocation of resources, and targeting of follow-ups among high-risk persons, promoting precision maternal care.

10.2 Artificial Intelligence and Predictive Algorithms for Maternal Health

Machine learning algorithms and artificial intelligence (AI) can be highly promising in the analysis of multifaceted immunogenomic data [2]. Through the combination of various types of data, such as the expression of genes, the epigenetic signature, and clinical factors, AI can recognize predictive patterns of postpartum infection, autoimmune exacerbations, or mood disorders. Predictive modeling has the potential to facilitate proactive care, an individualized treatment regimen, and the real-time surveillance of risks and eventually enhance the outcomes of mothers and decrease the occurrence of adverse events in the postpartum period.

10.3 Integrate the Wearable Biosensor Data with Immunogenomic Markers

Wearable biosensors combined with immunogenomics are a new technology that can be used to conduct dynamic postpartum monitoring [2]. The physiological parameters, including variability of heart rate, temperature, and inflammatory biomarker surrogates, were continuously monitored and associated with immunogenomic profiles. This combination means that immune dysregulation, infections, or inflammatory flares can be identified early in time, and actionable information is available to conduct personalized interventions.

10.4 Expanding the Research on the Paternal and Fetal Genomic Influences

There is emerging evidence that maternal immune adaptation is not just a matter of maternal genetics but also paternal and fetal genomic factors [1,2]. Future studies need to examine the impact of these interactions on postpartum immune patterns, complication susceptibility, and maternal and child health outcomes in the long run [46]. The knowledge of these intergenerational genomic effects may help optimize prediction models and guide family-focused interventions on postpartum care.

10.5 Future of the Next-Generation Personalized Postpartum Care Roadmap

The development of a roadmap of personalized postpartum care ought to include longitudinal immunogenomic surveillance and predictive modeling based on artificial intelligence (AI) and be intertwined with lifestyle and environmental data. These efforts should be based on standardized multiomic protocols, ethical data governance, and fair access. The following research directions are needed: the determination of actionable biomarkers, the creation of minimally invasive sampling protocols, and the establishment of scalable clinical procedures. Finally, the strategy may facilitate personalized treatment plans that maximize maternal recovery, avoid complications, and support the long-term health of both mother and child.

11. Conclusion

The postpartum period is marked by a rapid and highly dynamic immunological transition, as the maternal immune system shifts from pregnancy-associated tolerance to an inflammatory, reparative, and memory-forming state. Recent immunogenomic advances, including single-cell and spatial transcriptomics, epigenomic profiling, TCR/BCR repertoire sequencing, multiomic integration, and machine-learning analytics, have illuminated postpartum-specific gene signatures, sustained inflammatory pathways, hormonal imprinting, and microbiome-immune crosstalk. These insights clarify the molecular mechanisms underlying key postpartum morbidities, including infection, sepsis, hypertensive complications, autoimmune flares, impaired wound healing, and postpartum depression.

Critically, integrative immunogenomic studies have identified specific predictive biomarkers, such as persistent pro-inflammatory cytokines (IL-6, TNF-α), cell-type-specific transcriptomic patterns, microbiome-derived indicators, and polygenic risk profiles, that surpass conventional clinical parameters in forecasting adverse postpartum outcomes. These biomarkers enable precision postpartum medicine by informing individualized risk stratification, early diagnosis, and targeted interventions, thereby shifting care from a reactive model to a proactive, preventive framework.

Future priorities include establishing large, ethnically diverse longitudinal cohorts from late pregnancy through the first postpartum year; standardizing multiomic sampling and analytic pipelines; increasing inclusion of underrepresented populations; and ensuring equitable clinical translation, particularly in low- and middle-income settings. Through interdisciplinary collaboration and responsible implementation, immunogenomics can transform the postpartum period into a strategic window for improving maternal recovery, mental health, and long-term intergenerational health outcomes, demonstrating the concrete value of predictive biomarkers in precision medicine.

Conflict of Interest

The authors declare no conflicts of interest regarding the publication of this article.

Generative AI Statement

The authors declare that no Gen AI was used in the creation of this manuscript.

References

[1] Huang XB, Wang LL, Zhao SJ, Liu H, Chen S, Wu L, et al. Pregnancy induces an immunological memory characterized by maternal immune alterations through specific gene methylation. Frontiers in Immunology, 2021, 12, 686676. DOI: 10.3389/fimmu.2021.686676

[2] Wright M, Goin DE, Smed MK, Jewell NP, Nelson JL, Olsen J, et al. Pregnancy-associated systemic gene expression compared to a pre-pregnancy baseline, among healthy women with term pregnancies. Frontiers in Immunology, 2023, 14, 1161084. DOI: 10.3389/fimmu.2023.11084

[3] Brummaier T, Rinchai D, Toufiq M, Karim MY, Habib T, Utzinger J, et al. Design of a targeted blood transcriptional panel for monitoring immunological changes accompanying pregnancy. Frontiers in Immunology, 2024, 15, 1319949. DOI: 10.3389/fimmu.2024.1319949

[4] Peterson LS, Stelzer IA, Tsai AS, Ghaemi MS, Han X, Ando K, et al. Multiomic immune clockworks of pregnancy. Seminars in Immunopathology, 2020, 42(4), 397-412. DOI: 10.1007/s00281-019-00772-1

[5] Lv M, Jia YH, Dong JQ, Wu SY, Hao Y. The landscape of decidual immune cells at the maternal-fetal interface in parturition and preterm birth. Inflammation Research, 2025, 74(1), 44. DOI: 10.1007/s00011-025-02015-6

[6] Castelucci BG, Pereira AHM, Fioramonte M, Carazzolle MF, de Oliveira PSL, Franchini KG, et al. Evidence of macrophage modulation in the mouse pubic symphysis remodeling during the end of first pregnancy and postpartum. Scientific Reports, 2020, 10(1), 12406. DOI: 10.1038/s41598-020-68676-x

[7] Ozarslan N, Robinson JF, Buarpung S, Kim MY, Ansbro MR, Akram J, et al. Gravidity influences distinct transcriptional profiles of maternal and fetal placental macrophages at term. Frontiers in Immunology, 2024, 15, 1384374. DOI: 10.3389/fimmu.2024.1384374

[8] Giles M, Cole SR, O'Bryan J, Krishnaswamy S, Ben-Othman R, Amenyogbe N, et al. The protective effect of maternal immunisation on preTerm birth: Underlying mechanisms and role in newborn immune function: Study protocol. Frontiers in Immunology, 2023, 14, 1212320. DOI: 10.3389/fimmu.2023.1212320

[9] Kothiyal P, Schulkers K, Liu X, Hazrati S, Vilboux T, Gomez LM, et al. Differences in maternal gene expression in Cesarean section delivery compared with vaginal delivery. Scientific Reports, 2020, 10(1), 17789. DOI: 10.1038/s41598-020-74989-8

[10] Pique-Regi R, Romero R, Garcia-Flores V, Peyvandipour A, Tarca AL, Pusod E, et al. A single-cell atlas of the myometrium in human parturition. JCI Insight, 2022, 7(5), e153921. DOI: 10.1172/jci.insight.153921

[11] Couture C, Brien ME, Rechtzigel J, Ling S, Ledezma-Soto C, Duran Bishop G, et al. Predictive biomarkers and initial analysis of maternal immune alterations in postpartum preeclampsia reveal an immune-driven pathology. Frontiers in Immunology, 2024, 15, 1380629. DOI: 10.3389/fimmu.2024.1380629

[12] Cao C, Saxena R, Gray KJ. Placental origins of preeclampsia: Insights from multiomic studies. International Journal of Molecular Sciences, 2024, 25(17), 9343. DOI: 10.3390/ijms25179343

[13] Zarnani A, Jeddi-Tehrani M, Piccinni M, Zenclussen ML. Editorial: Immunology at the feto-maternal interface. Frontiers in Immunology, 2025, 16, 1667375. DOI: 10.3389/fimmu.2025.1667375

[14] Mantovani A, Garlanda C. Humoral innate immunity and acute-phase proteins. The New England Journal of Medicine, 2023, 388(5), 439-452. DOI: 10.1056/NEJMra2206346

[15] Fernando M, Ellery SJ, Marquina C, Lim S, Naderpoor N, Mousa A. Vitamin D-binding protein in pregnancy and reproductive health. Nutrients, 2020, 12(5), 1489. DOI: 10.3390/nu12051489

[16] Wang SS, Xu R, Li G, Liu SP, Zhu J, Gao PF. A plasma proteomics-based model for identifying the risk of postpartum depression using machine learning. Journal of Proteome Research, 2025, 24(2), 824-833. DOI: 10.1021/acs.jproteome.4c00826

[17] Hasin Y, Seldin M, Lusis A. Multiomics approaches to disease. Genome Biology, 2017, 18(1), 83. DOI: 10.1186/s13059-017-1215-1

[18] Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 2019, 25, 44-56. DOI: 10.1038/s41591-018-0300-7

[19] Dickens MJ, Pawluski JL, Romero LM. Moving forward from COVID-19: Bridging knowledge gaps in maternal health with a new conceptual model. Frontiers in Global Women's Health, 2020, 1, 586697. DOI: 10.3389/fgwh.2020.6697

[20] Abu-Raya B, Michalski C, Sadarangani M, Lavoie PM. Maternal immunological adaptation during normal pregnancy. Frontiers in Immunology, 2020, 11, 519751. DOI: 10.3389/fimmu.2020.575197

[21] Sharma S, Rodrigues P, Zaher S, Davies LC, Ghazal P. Immune-metabolic adaptations in pregnancy: A potential stepping-stone to sepsis. EBioMedicine, 2022, 86, 104337. DOI: 10.1016/j.ebiom.2022.104337

[22] Wu SC, Rau CS, Kuo PJ, Shih FY, Lin HP, Wu YC, et al. Profiling the expression of circulating acute-phase proteins, cytokines, and checkpoint proteins in patients with severe trauma: A pilot study. Journal of Inflammation Research, 2021, 14, 3739-3753. DOI: 10.2147/JIR.S324056

[23] Herrock O, Deer E, LaMarca B. Setting a stage: Inflammation during preeclampsia and postpartum. Frontiers in Physiology, 2023, 14, 1130116. DOI: 10.3389/fphys.2023.1130116

[24] Clephane K, Lorenz TK. Putative mental, physical, and social mechanisms of hormonal influences on postpartum sexuality. Current Sexual Health Reports, 2021, 13(4), 136-148. DOI: 10.1007/s11930-021-00321-8

[25] Weng J, Couture C, Girard S. Innate and adaptive immune systems in physiological and pathological pregnancy. Biology, 2023, 12(3), 402. DOI: 10.3390/biology12030402

[26] Zhang YJ, Shen L, Zhang T, Muyayalo KP, Luo J, Mor G, et al. Immunologic memory in pregnancy: Focusing on memory regulatory T cells. International Journal of Biological Sciences, 2022, 18(6), 2406-2418. DOI: 10.7150/ijbs.70629

[27] Yeung HY, Dendrou CA. Pregnancy immunogenetics and genomics: Implications for pregnancy-related complications and autoimmune disease. Annual Review of Genomics and Human Genetics, 2019, 20(1), 73-97. DOI: 10.1146/annurev-genom-083118-014943

[28] Rahnavard A, Chatterjee R, Wen H, Gaylord C, Mugusi S, Klatt KC, et al. Molecular epidemiology of pregnancy using omics data: Advances, success stories, and challenges. Journal of Translational Medicine, 2024, 22(1), 106. DOI: 10.1186/s12967-024-04876-7
[29] Barrientos G, Solano ME, Blois SM, Sharma SK. Editorial: The placenta, fetomaternal tolerance and beyond: A tribute to Sir Peter Medawar on the 60th anniversary of his Nobel Prize. Frontiers in Immunology, 2022, 13, 1021885. DOI: 10.3389/fimmu.2022.1021885
[30] Alippe Y, Hatterschide J, Coyne CB, Diamond MS. Innate immune responses to pathogens at the maternal-fetal interface. Nature Reviews Immunology, 2025, 25(12), 869-884. DOI: 10.1038/s41577-025-01191-0
[31] Ma XQ, Chen X, Mu XF, Cao M, Zhang Y. Epigenetics of maternal-fetal interface immune microenvironment and placental-related pregnancy complications. Frontiers in Immunology, 2025, 16, 1549839. DOI: 10.3389/fimmu.2025.1549839
[32] Yu X, Xiang H, Huang X. Single-cell transcriptome and RNA sequencing reveal immune-related markers of preeclampsia. Reproductive Sciences, 2025, 32(8), 2819-2828. DOI: 10.1007/s43032-025-01843-5
[33] Kharb S, Joshi A. Multiomics and machine learning for the prevention and management of female reproductive health. Frontiers in Endocrinology, 2023, 14, 1081667. DOI: 10.3389/fendo.2023.1081667
[34] Addala V, Newell F, Pearson JV, Redwood A, Robinson BW, Creaney J, et al. Computational immunogenomic approaches to predict response to cancer immunotherapies. Nature Reviews Clinical Oncology, 2024, 21, 28-46. DOI: 10.1038/s41571-023-00830-6
[35] Lopez Zapana PA, Shook LL, Joughin BA, Jasset OJ, Liu ZA, Yinger RV, et al. Maternal proteome profiling reveals dynamic gestational age-specific responses to de novo vaccination. The Journal of Immunology, 2026, 215(2), vkaf298. DOI:10.1093/jimmun/vkaf298
[36] Mehta D, Grewen K, Pearson B, Wani S, Wallace L, Henders AK, et al. Genome-wide gene expression changes in postpartum depression point towards an altered immune landscape. Translational Psychiatry, 2021, 11(1), 155. DOI:10.1038/s41398-021-01270-5
[37] Islam SMS, Talukder A, Awal MA, Siddiqui MMU, Ahamad MM, Ahammed B, et al. Machine learning approaches for predicting hypertension and its associated factors using population-level data from three South Asian countries. Frontiers in Cardiovascular Medicine, 2022, 9, 839379. DOI: 10.3389/fcvm.2022.839379
[38] Ozen M, Aghaeepour N, Maric I, Wong RJ, Stevenson DK, Jantzie LL. Omics approaches: Interactions at the maternal-fetal interface and origins of child health and disease. Pediatric Research, 2023, 93(2), 366-375. DOI: 10.1038/s41390-022-02335-x
[39] Modzelewski S, Oracz A, Iłendo K, Sokół A, Waszkiewicz N. Biomarkers of postpartum depression: A narrative review. Journal of Clinical Medicine, 2023, 12(20), 6519. DOI:10.3390/jcm12206519
[40] Gaál Z. Role of microRNAs in immune regulation with translational and clinical applications. International Journal of Molecular Sciences, 2024, 25(3), 1942. DOI: 10.3390/ijms25031942
[41] Fu XX, Li YL, Zhang Z, Wang B, Wei R, Chu C, et al. Emerging role of miRNAs, lncRNAs, and circRNAs in pregnancy-associated diseases. Chinese Medical Journal, 2023, 136(11), 1300-1310. DOI: 10.1097/CM9.0000000000002595
[42] Graf I, Hecher K, Arck P. Immunologie der Schwangerschaft: Von lokalen und systemischen Protagonisten zum high-content-immunprofiling. Die Gynäkologie, 2022, 55, 631-639. DOI: 10.1007/s00129-022-04973-y
[43] Zenere A. Integration of epigenetic, transcriptomic and proteomic data. Linköping: Linköping University Electronic Press, 2023. DOI: 10.3384/9789180750691
[44] Seo K, Choi JK. Comprehensive analysis of TCR and BCR repertoires: Insights into methodologies, challenges, and applications. Genomics & Informatics, 2025, 23(1), 6. DOI: 10.1186/s44342-024-00034-z
[45] Saso A, Kampmann B. Maternal immunization: Nature meets nurture. Frontiers in Microbiology, 2020, 11, 1499. DOI: 10.3389/fmicb.2020.01499
[46] Wu XQ, Jin R. Effects of postpartum hormonal changes on the immune system and their role in recovery. Acta Biochimica Polonica, 2025, 72, 14241. DOI: 10.3389/abp.2025.14241
[47] Ross KM, Schetter CD, Carroll JE, Mancuso RA, Breen EC, Okun ML, et al. Inflammatory and immune marker trajectories from pregnancy to one-year post-birth. Cytokine, 2022, 149, 155758. DOI: 10.1016/j.cyto.2021.155758
[48] Paquette AG, MacDonald J, Bammler T, Day DB, Loftus CT, Buth E, et al. Placental transcriptomic signatures of spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2023, 228(1), 73.e1-73.e18. DOI: 10.1016/j.ajog.2022.07.015
[49] Bai LL, Guo YY, Gong JX, Li YC, Huang HF, Meng YC, et al. Machine learning and bioinformatics framework integration reveal potential characteristic genes related to immune cell infiltration in preeclampsia. Frontiers in Physiology, 2023, 14, 1078166. DOI: 10.3389/fphys.2023.1078166
[50] Saurabh R, Fouodo CJ, König IR, Busch H, Wohlers I. A survey of genome-wide association studies, polygenic scores and UK Biobank highlights resources for autoimmune disease genetics. Frontiers in Immunology, 2022, 13, 972107. DOI: 10.3389/fimmu.2022.972107
[51] Sha Q, Yu QN, Chen KX, Wang JY, Wang FY, Jiang C, et al. Spatial transcriptomics of human decidua identifies molecular signatures in recurrent pregnancy loss. Genomics, Proteomics & Bioinformatics, 2025, qzaf080. DOI: 10.1093/gpbjnl/qzaf080
[52] Li R, Wang TY, Xu X, Emery OM, Yi M, Wu SP, et al. Spatial transcriptomic profiles of mouse uterine microenvironments at pregnancy day 7.5. Biology of Reproduction, 2022, 107(2), 529-545. DOI: 10.1093/biolre/ioac061
[53] Jiang H, Qu JX, Huang NN, Li ZL, Shi XM, Chen LA, et al. Integrative multiomic analysis reveals potential biomarkers in the cervicovaginal fluid of patients with placenta accrete spectrum. BMC Pregnancy Childbirth, 2024, 24, 856. DOI: 10.1186/s12884-024-07065-y
[54] Graf I, Urbschat C, Arck P. The 'communicatome' of pregnancy: Spotlight on cellular and extravesicular chimerism. EMBO Molecular Medicine, 2024, 16(4), 700-714. DOI: 10.1038/s44321-024-00045-x
[55] Su JJ, Wang Y, Li Q, Yin ZW, Liu QB, Yang LL, et al. Deconvoluting the heterogeneities of immune cells at the maternal-fetal interface of mice across pregnancy. Reproduction, 2025, 170(6), e250090. DOI: 10.1530/REP-25-0090